The Global Pulmonary Arterial Hypertension market is projected to exhibit a CAGR of over 4.95% during 2016-2021.
The report suggests that rising development of pipeline drugs in PAH combined with the growing awareness of the disease majorly in developed countries has resulted in the growth of PAH market. Also, the market for Pulmonary Arterial Hypertension (PAH) is growing moderately due to newer launches of pipeline drugs that target different pathways to supress the symptoms of the disease. Early diagnosis of the disease has played a pivotal role in number of patients undergoing treatment.
While developed regions will continue to dominate the market in terms of revenue, emerging nations are expected to respond to the market optimistically due to the developing healthcare infrastructure and rising focus on healthcare among the growing middle class population.
Among the drug classes, the market is expected to be driven by ERAs. However, growing number of drugs under prostacyclin are expected to witness tremendous growth in the forecast period.